Hormonal therapies and gynaecological cancers.
Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma. There is no place for adjuvant hormonal treatment of these cancers after primary surgery. Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases. Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%. To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published.
Garrett
Andrea
A
Mercy Hospital for Women, Heidelberg, Victoria 3084, Australia. AGarrett@mercy.com.au
Quinn
Michael A
MA
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy; D015914:Estrogen Replacement Therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011372:Progestins / Q000627:therapeutic use; D018203:Sarcoma, Endometrial Stromal / Q000188:drug therapy; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011372:Progestins; D013629:Tamoxifen